Introduction
Sublethal preconditioning ischemia prevents delayed neuronal cell death in the rodent and gerbil hippocampus CA1 region after a severe ischemic insult, a phenomenon known as ischemic tolerance (Kitagawa et al., 1990; Kirino et al., 1991; Kirino, 2002; Obrenovitch, 2008) . Despite intense study, the mechanisms underlying ischemic tolerance in the brain are not fully understood. A robust elevation of the excitatory neurotransmitter glutamate has been implicated to have a critical role in induction of delayed neuronal cell death following cerebral ischemia (Szatkowski and Attwell, 1994; Arundine and Tymianski, 2004; Hara and Snyder, 2007) . The overactivation of N-methyl-D-aspartate (NMDA) receptors by the excess glutamate is widely considered to mediate the delayed neuronal death in the hippocampal CA1 region following global cerebral ischemia (Gee et al., 2006; Liu et al., 2007; Benquet et al., 2008) . However, mild activation of NMDA receptors has been suggested to actually exert a potential beneficial neuroprotective action in the hippocampus and other brain regions (Kato et al., 1992; Bond et al., 1999; Grabb and Choi, 1999; Miao et al., 2005; Soriano et al., 2006) . Along these lines, NMDA receptors have been shown to play a key role in preconditioning neuroprotection as evidenced by the finding that preconditioning with low doses of NMDA protect against both apoptotic and excitotoxic insults (Jiang et al., 2005; Soriano et al., 2006) , and by the fact that administration of NMDA receptor antagonists abolishes Previous work has demonstrated that ischemic preconditioning neuroprotection is associated with inhibition of JNK pathway activation. The present study was designed to examine the hypothesis that the suppression of JNK3 activation by preconditioning is mediated by NMDA receptors and crosstalk between ERK1/2 and JNK3. Preconditioning (3 min ischemia) 2 days before global cerebral ischemia (8-min) markedly decreased neuronal degeneration in hippocampus CA1, an effect abolished by pretreatment with the NMDA receptor antagonist, MK-801. Furthermore, preconditioning abolished cerebral ischemia-induced JNK3 activation and enhanced ERK1/2 activation, an effect reversed by MK-801. Due to the inverse relationship between ERK1/2 and JNK3 activation following preconditioning, we hypothesized that ERK1/2 may regulate JNK3 activation following preconditioning. In support of this contention, pretreatment with the MEK inhibitor, PD98059 significantly attenuated preconditioninginduced ERK1/2 phosphorylation, and strongly reversed preconditioning down-regulation of JNK3 phosphorylation. This finding suggests that ERK1/2 signaling is responsible for preconditioning-induced down-regulation of JNK3 activation. Western blot analysis and immunohistochemistry further demonstrated that preconditioning, in an NMDA-dependent manner, enhanced activation of the prosurvival factors, p-CREB and Bcl-2, while attenuating activation of putative pro-death factors, p-c-Jun and Fas-L in the hippocampus CA1. As a whole, the study demonstrates that preconditioning attenuation of pro-death JNK3 in the hippocampus CA1 following global cerebral ischemia is mediated by NMDA receptor-induced crosstalk between ERK1/2 and JNK3. The ERK1/2-mediated reduction of JNK3 activation leads to enhanced pro-survival signaling (P-CREB and Bcl-2 induction) and attenuation of prodeath signaling (p-c-Jun and Fas-L), with subsequent induction of ischemic tolerance.
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